Detalles de la búsqueda
1.
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Ann Hematol
; 100(8): 2005-2014, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33388860
2.
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Ann Hematol
; 99(7): 1525-1530, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32474619
3.
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Hematol Oncol
; 37(3): 296-302, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30892724
4.
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib.
Hematol Oncol
; 38(4): 607-610, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32602167
5.
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.
Am J Hematol
; 93(7): E159-E161, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29633312
6.
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.
Int J Cardiol
; 301: 163-166, 2020 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31711851
7.
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study.
Blood Cancer J
; 10(6): 66, 2020 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32514110
Resultados
1 -
7
de 7
1
Próxima >
>>